{"title":"Precision medicine in drug safety","authors":"Daniel F. Carr, Munir Pirmohamed","doi":"10.1016/j.cotox.2020.07.003","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>Over the past two decades, our understanding of genetic heritability has been derived from candidate gene and genome-wide studies looking at common allelic variant associations. As our access to advanced genomics technologies increases, so too does the availability of </span>pharmacogenomic<span> data for predicting the risk of adverse drug reactions (ADRs). We now have the ability to look at the contribution of rare and even </span></span>personal genomic variants on ADR risk. However, the increase in data will be accompanied by challenges in interpretation and implementation. This review looks at the current position of drug safety pharmacogenomics and discusses the challenges, as well as some possible future directions.</p></div>","PeriodicalId":37736,"journal":{"name":"Current Opinion in Toxicology","volume":"23 ","pages":"Pages 87-97"},"PeriodicalIF":3.6000,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cotox.2020.07.003","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Toxicology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468202020300462","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"TOXICOLOGY","Score":null,"Total":0}
引用次数: 3
Abstract
Over the past two decades, our understanding of genetic heritability has been derived from candidate gene and genome-wide studies looking at common allelic variant associations. As our access to advanced genomics technologies increases, so too does the availability of pharmacogenomic data for predicting the risk of adverse drug reactions (ADRs). We now have the ability to look at the contribution of rare and even personal genomic variants on ADR risk. However, the increase in data will be accompanied by challenges in interpretation and implementation. This review looks at the current position of drug safety pharmacogenomics and discusses the challenges, as well as some possible future directions.
期刊介绍：
The aims and scope of Current Opinion in Toxicology is to systematically provide the reader with timely and provocative views and opinions of the highest qualified and recognized experts on current advances in selected topics within the field of toxicology. The goal is that Current Opinion in Toxicology will be an invaluable source of information and perspective for researchers, teachers, managers and administrators, policy makers and students. Division of the subject into sections: For this purpose, the scope of Toxicology is divided into six selected high impact themed sections, each of which is reviewed once a year: Mechanistic Toxicology, Metabolic Toxicology, Risk assessment in Toxicology, Genomic Toxicology, Systems Toxicology, Translational Toxicology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
